Due to their rarity, rare lipoprotein disorders are largely under-recognised and undertreated.
This is not surprising, as given their infrequency, clinicians may only see one or
two affected people in their entire careers and misdiagnosis is therefore common.
Furthermore, the fact that there are currently very few disease-specific rare lipoprotein
disorder patient registries, means that there is a scarcity of quality information
about the prevalence, pathophysiology, and outcomes of these disorders. Evidence-based
clinical management of these conditions is therefore problematic.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic and PersonalCorporate R&D ProfessionalsOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Orphan designation: overview.https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overviewDate accessed: April 4, 2019
- Rare Diseases Act of.2002https://www.govinfo.gov/content/pkg/PLAW-107publ280/html/PLAW-107publ280.htmlDate accessed: April 4, 2019
- Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement.Lancet Diabetes Endocrinol. 2019; (Link:)https://doi.org/10.1016/S2213-8587(19)30264-5
- Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217.Eur. Heart J. 2016; 37: 1384-1394
- Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.Nature. 2015; 518: 102-106
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.Eur. Heart J. 2014; 35: 2146-2157
- The complex molecular genetics of familial hypercholesterolaemia.Nat. Rev. Cardiol. 2019; 16: 9-20
- Current role of lipoprotein apheresis in the treatment of high-risk patients.J Cardiovasc Dev Dis. 2018; 5: e27
- Lipid-lowering agents.Circ. Res. 2019; 124: 386-404
- ANGPTL3 inhibition in homozygous familial hypercholesterolemia.N. Engl. J. Med. 2017; 377: 296-297
- Chylomicronaemia—current diagnosis and future therapies.Nat. Rev. Endocrinol. 2015; 11: 352-362
- Severe hypertriglyceridemia is primarily polygenic.J Clin Lipidol. 2019; 13: 80-88
- Genetics of triglycerides and the risk of atherosclerosis.Curr. Atheroscler. Rep. 2017; 19: 31
- Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.J Clin Lipidol. 2018; 12: 920-927
- Genetic and secondary causes of severe HDL deficiency and cardiovascular disease.J. Lipid Res. 2018; 59: 2421-2435
- Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA.J. Lipid Res. 2015; 56: 703-712
- Safety and tolerability of ACP-501, a recombinant human lecithin: cholesterol acyltransferase, in a phase 1 single-dose escalation study.Circ. Res. 2016; 118: 73-82
- Lecithin: cholesterol acyltransferase activation by sulfhydryl-reactive small molecules: role of cysteine-31.J. Pharmacol. Exp. Ther. 2017; 362: 306-318
Article Info
Publication History
Published online: December 18, 2019
Accepted:
December 12,
2019
Received:
December 12,
2019
Identification
Copyright
© 2019 Elsevier B.V. All rights reserved.
